
    
      In November 2009 it was the company's decision to cancel this study as an international
      trial. However, to support the local MA application of Aspirin i.v. for the indication "For
      the initial treatment in case of suspicion of acute coronary syndrome", Bayer decided to
      perform this trial in Germany as a domestic trial, with changed number of participants and
      study dates.
    
  